Notably, patients with melanoma subjected to treatment with the anti-CTLA-4 antibody, ipilimumab, exhibited a marked reduction in granulocyte levels, suggesting a potential dearth of synergistic interaction between CTLA4 and neutrophils [178]. Here, CTLA4 is linked to melanoma.